Eric J. Feldman

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

Alan F. List, Gordon W. Dewald, John M. Bennett et al. · New England Journal of Medicine · 2006 · 1.3K citations

Medicine, Hematology, Pharmacology +17

Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3

Thomas Fischer, Richard M. Stone, Daniel J. DeAngelo et al. · Journal of Clinical Oncology · 2010 · 502 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1–risk myelodysplastic syndromes with karyotypes other than deletion 5q

Azra Raza, James A. Reeves, Eric J. Feldman et al. · Blood · 2007 · 423 citations · Full text

Medicine, Hematology, Oncology +16

Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML

Jeffrey E. Lancet, Jörge E. Cortes, Donna E. Hogge et al. · Blood · 2014 · 336 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +6

First-In-Man Study of CPX-351: A Liposomal Carrier Containing Cytarabine and Daunorubicin in a Fixed 5:1 Molar Ratio for the Treatment of Relapsed and Refractory Acute Myeloid Leukemia

Eric J. Feldman, Jeffrey E. Lancet, Jonathan E. Kolitz et al. · Journal of Clinical Oncology · 2011 · 300 citations · Full text

Medicine, Clinical Pharmacokinetics, Pharmacology +17